title: Does hepatitis C virus affect the reactivation of hepatitis B virus following renal transplantation?
abstract: BACKGROUND
  Hepatitis B virus (HBV) is endemic in Taiwan. Transplantation followed by long-term immunosuppressive medications may precipitate HBV reactivation. Interference of hepatitis C virus (HCV) with HBV gene expression and replication has been confirmed in many studies involving non-transplant populations. This study investigates the incidence of HBV reactivation following renal transplantation and compares the clinical outcome, especially the liver outcome, of patients with or without HCV co-infection.
  
  
  METHODS
  Fifty-one of 512 renal transplant recipients were positive for hepatitis B surface antigen before surgery, and were followed for 81.6+/-7.5 (4-120) months. Seventeen of 51 patients acquired HCV before transplantation and six patients acquired HCV after renal transplantation.
  
  
  RESULTS
  At the end of this assessment, we had 28 patients who suffered HBV reactivation and another 23 patients who suffered no HBV reactivation. Initially, we found a significant difference of HCV carriage (P<0.05) between patients with (seven out of 28 or 25%) or without (21 out of 23 or 91.3%) HBV reactivation. Further inspection showed that 21 of the 28 patients without HCV co-infection and seven of the 23 patients with HCV co-infection suffered HBV reactivation. After comparison, we found a lower incidence of HBV reactivation in patients with HCV co-infection than in patients without HCV co-infection (P<0.05). In contrast to the latter, we found that patients with HCV co-infection suffering HBV reactivation tended to have a late onset of HBV reactivation (P<0.05). Otherwise, there was no difference in hepatitis severity, in terms of peak alanine aminotransferase, total bilirubin levels and hepatitis reactivation-related death, between these two groups of patients. Finally, a multivariable analysis also revealed that HCV carriage was indeed an independent variable leading to the reduced incidence of HBV reactivation in patients with HCV co-infection.
  
  
  CONCLUSIONS
  HCV might affect the reactivation of HBV by decreasing the incidence or delaying the onset of HBV reactivation in renal transplant recipients carrying both HBV and HCV.
authors.affiliation: Department of Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan.
authors.forename: Tzung-Hai
authors.initials: TH
authors.lastname: Yen
authors.forename: Chiu-Ching
authors.initials: CC
authors.lastname: Huang
authors.forename: Hsin-Hung
authors.initials: HH
authors.lastname: Lin
authors.forename: Jeng-Yi
authors.initials: JY
authors.lastname: Huang
authors.forename: Ya-Chun
authors.initials: YC
authors.lastname: Tian
authors.forename: Chih-Wei
authors.initials: CW
authors.lastname: Yang
authors.forename: Mai-Szu
authors.initials: MS
authors.lastname: Wu
authors.forename: Ji-Tseng
authors.initials: JT
authors.lastname: Fang
authors.forename: Chun-Chen
authors.initials: CC
authors.lastname: Yu
authors.forename: Yang-Jen
authors.initials: YJ
authors.lastname: Chiang
authors.forename: Sheng-Hsieh
authors.initials: SH
authors.lastname: Chu
mesh_terms: D000328:Adult; D005260:Female; D006085:Graft Survival; D016174:Hepacivirus / Q000502:physiology*; D006509:Hepatitis B / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000502:physiology*; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D016030:Kidney Transplantation; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D014775:Virus Activation
chemical_list: D006514:Hepatitis B Surface Antigens; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine